Co-Diagnostics Q3 revenue $5.1M (down 83% YoY); net loss $1.4M vs prior-year income $11.5M

Co-Diagnostics, Inc.

2022-Q3 EPS reported $0.23 revenue$32,816,726

Revenue $5.1M, down from $30.1M a year ago; operating loss $6.5M vs income $13.6M.
Net loss $1.4M ($0.04 loss per diluted share) vs net income $11.5M in Q3 2021.
Adjusted EBITDA loss $4.1M; cash, equivalents, and marketable securities $86.5M.
Repurchased 2.9M shares at avg $3.61; generated $1.1M operating cash flow in Q3.
Co-Dx PCR Home platform nearing clinical evaluations; shipped Monkeypox test and appointed new CSO Dr. Mark Poritz.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Co-Diagnostics, Inc. reported the third quarter ended September 30, 2022 results: revenue Revenue of $5.1 million, net income Net loss of $1.4 million, EPS loss of $0.04 per fully diluted share.

Period: the third quarter ended September 30, 2022
Revenue: Revenue of $5.1 million
Net income: Net loss of $1.4 million
EPS: loss of $0.04 per fully diluted share
Result: reported results

Exact text from the filing

development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results: ● Revenue of $5.1 million, down from $30.1 million during the prior year period, but an increase of 1.4% from the current year second quarter ● Gross profit of $4.3 million, representing 84.9% of

View on SEC.gov

Browse all earnings releases →

Co-Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.